MEDVi Review 2026
Reviewed August 7, 2026 · Both — compounded semaglutide and tirzepatide (injections and tablets), plus brand-name Wegovy and Zepbound. Compounded products are not FDA-approved.
Visit MEDVi WebsiteOverview
MEDVi is a telehealth weight-loss platform selling compounded semaglutide and tirzepatide as both injections and oral tablets, alongside brand-name Wegovy and Zepbound. Its plan inclusions are better than most: free dietitian visits and care coaching, 24/7 support, and free expedited delivery, with HSA/FSA accepted and no insurance required. It is a real, operating company using licensed US physicians, and its Trustpilot sentiment is comparatively good for this category. All of that is genuinely in its favour, and this review would ordinarily land in the middle of the pack. It does not, for one reason that overrides the rest. On 20 February 2026 the FDA's Center for Drug Evaluation and Research issued MEDVi, LLC a warning letter — MARCS-CMS 721455 — finding that its website made false or misleading claims about its compounded semaglutide and tirzepatide products, rendering them misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. We verified this letter directly in the FDA's own warning letter database rather than relying on secondary coverage. Two findings stand out. First, the compounded products pictured on MEDVi's site carried labels identifying 'MEDVi' as the compounder 'when in fact it is not'. Second, claims that the products contained the 'Same active ingredient as Wegovy® and Ozempic®' and the 'Same active ingredient as Mounjaro® and Zepbound®' were found to imply FDA approval the products do not have. Compounding this, the offer page we checked displayed broken template code instead of prices, and its 'no membership or hidden fees' claim sits directly above a $99 membership tier.
Medications Offered
Brand-name or compounded: Both — compounded semaglutide and tirzepatide (injections and tablets), plus brand-name Wegovy and Zepbound. Compounded products are not FDA-approved.
- Compounded semaglutide injections — price not displayed on the page we checked
- Compounded semaglutide tablets — price not displayed on the page we checked
- Compounded tirzepatide options
- Brand-name Wegovy pill and Wegovy injection — '$99 Membership + Medication Cost'
- Brand-name Zepbound injection — '$99 Membership + Medication Cost'
- MEDVi states compounded GLP-1s 'are produced in FDA-regulated facilities' but 'are not FDA-approved or evaluated for safety, efficacy, or quality'
Consultation Process
Online intake
You complete an online medical intake. MEDVi states no insurance is required and clinician approval is needed before anything is dispensed.
Clinician review
A licensed US physician or nurse practitioner reviews the intake and prescribes if appropriate.
Order passes to the pharmacy
This is the commercially critical step. Reporting on MEDVi's terms indicates that once an order is placed and has passed to a provider and then automatically to the pharmacy, it is no longer refundable. Confirm this in writing before paying.
Delivery and support
Medication ships with free expedited delivery. Dietitian visits, care coaching and 24/7 support are included in the plan.
Eligibility
- Adults; MEDVi does not publish a BMI threshold or age range
- Clinician approval required
- No insurance required — cash-pay service
- State availability is not published
- Standard GLP-1 contraindications apply
Provider Involvement
MEDVi uses licensed US physicians and includes free dietitian visits and care coaching in its plans, which is more clinical support than most cash-pay compounded platforms provide and is a real point in its favour. No medical director or named clinician is published, and the FDA warning letter concerned the company's marketing rather than its clinical care.
Lab Requirements
Not published. No required panel appears on the pages we reviewed. Ask what monitoring is expected before starting.
Pharmacy Fulfillment
Not named — and this is precisely what the FDA objected to. The agency's 20 February 2026 warning letter found that the compounded semaglutide and tirzepatide products displayed on MEDVi's website 'identify "MEDVi" on the pictured label, suggesting MEDVi is the compounder of those drugs when in fact it is not'. The FDA asked MEDVi to identify the entities that actually produce its compounded products. If you are considering this service, asking which pharmacy fills your prescription and what its 503A or 503B status is has rarely been more clearly justified.
Shipping Frequency
Free expedited delivery is included, but no delivery window or shipping cadence is published beyond 'shipped directly to your door'.
Membership Fees vs. Medication Fees
Membership fees
Contradictory as published. The offer page claims 'No membership or hidden fees' while simultaneously listing brand-name options at '$99 Membership + Medication Cost'. Both statements appear on the same page. Establish in writing which applies to the plan you are buying.
Medication fees
- Compounded injection and tablet prices were not rendered on the offer page we checked
- Brand-name Wegovy and Zepbound: '$99 Membership + Medication Cost', medication cost unstated
- Dietitian visits, care coaching, 24/7 support and expedited delivery: included
Cancellation & Refund Policy
Cancellation
Not published on the pages we reviewed. Given the reported no-refund-after-order position and the volume of billing complaints, confirm the cancellation process, notice period and renewal date in writing before providing payment details.
Refunds
Restrictive as reported, and not published clearly by the company. Secondary reporting indicates MEDVi does not permit refunds once an order has been placed and handed to a provider or nurse practitioner and then automatically to the pharmacy. Complaint records include a customer who says they were sent the wrong medication and then double-charged to correct the error. We could not locate a plainly published refund policy to verify these against, which is itself the problem.
Insurance
MEDVi states no insurance is required and operates as a cash-pay service. Brand-name Wegovy and Zepbound are offered on a membership-plus-medication basis rather than billed to a pharmacy benefit.
HSA / FSA
MEDVi states 'HSA/FSA Approved'. Confirm with your plan administrator.
See our GLP-1 insurance and HSA/FSA guide for how reimbursement works in practice.
Support Services
- Free dietitian visits included
- Care coaching included
- Unlimited 24/7 support
- Free expedited delivery
- HSA/FSA accepted
State Availability
Not published. No state list or exclusions appear on the pages we reviewed.
Pros
- Includes free dietitian visits and care coaching in the plan, which few competitors do
- Offers brand-name Wegovy and Zepbound alongside compounded product
- Compounded and oral tablet options as well as injections
- Free expedited delivery and 24/7 support included
- States HSA/FSA is accepted and no insurance is required
- Trustpilot sentiment is comparatively good for the category
Cons
- Received an FDA warning letter on 20 February 2026 for false or misleading claims about its compounded GLP-1s
- FDA found MEDVi's product labels identified MEDVi as the compounder when it is not
- The offer page we checked displayed unrendered template variables instead of prices
- Marketing says 'No membership or hidden fees' while the same page lists a '$99 Membership + Medication Cost' tier
- Reported to refuse refunds once an order has passed to a provider or pharmacy
- The BBB rates the company F
- Cancellation terms, contract length and state availability are not published
Who MEDVi May Be Best For
- Patients who want dietitian and coaching support bundled rather than sold separately
- Buyers who will insist on a written quote and written pharmacy identification before paying
Limitations
- An FDA warning letter on file for false or misleading claims about its compounded products
- Pricing not reliably displayed; template variables shown instead of figures
- Directly contradictory membership-fee messaging on the same page
- Refunds reportedly unavailable once an order reaches the pharmacy
- BBB F rating
- No published state list, cancellation terms or eligibility criteria
Reputation & Trust
This is the section that decides the rating, and the evidence is unusually concrete. On 20 February 2026 the FDA's Center for Drug Evaluation and Research issued a warning letter to MEDVi, LLC dba MEDVi of 131 Continental Dr, Ste 305, Newark, Delaware — MARCS-CMS 721455 — after reviewing the company's website in December 2025. The FDA found the compounded semaglutide and tirzepatide products displayed there were misbranded under sections 502(a) and 502(bb) of the FDCA on two grounds: the pictured labels identified MEDVi as the compounder 'when in fact it is not', and claims of the 'Same active ingredient as Wegovy® and Ozempic®' and 'Same active ingredient as Mounjaro® and Zepbound®' implied that compounded products 'have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not'. The letter gave MEDVi fifteen working days to respond and warned that failure to address the violations 'may result in legal action without further notice, including, without limitation, seizure and injunction'. We verified this in FDA's own database, not via secondary coverage. Context matters in both directions: MEDVi was one of 30 telehealth companies the FDA warned in an enforcement sweep announced on 3 March 2026, so this was an industry-wide action rather than a uniquely targeted one, and the letter concerns marketing rather than any finding about medication safety. Separately, the BBB rates MEDVi F, while Trustpilot sentiment is comparatively positive at around 4.5. Be careful with search results here — a separate and unrelated company, MEDvidi (medvidi.com), a mental health platform, is frequently confused with MEDVi in aggregated reviews.
What Makes MEDVi Different
- Free dietitian visits and care coaching included in the plan
- Oral tablet formulations as well as injections
- Brand-name Wegovy and Zepbound offered alongside compounded product
- 24/7 support and free expedited delivery included
Our Verdict
MEDVi scores 2/5. Stripped of the regulatory history, this would be a middling-to-decent option: free dietitian visits and care coaching are more clinical support than most cash-pay platforms include, oral tablets and brand-name Wegovy and Zepbound widen the choice, delivery and 24/7 support are free, and Trustpilot sentiment is comparatively good. But we cannot review the service as though the last six months did not happen. The FDA issued MEDVi a warning letter on 20 February 2026 finding its compounded GLP-1 products misbranded, specifically because the pictured labels named MEDVi as the compounder when it is not, and because 'same active ingredient as Wegovy®' claims implied an FDA approval the products do not have. We verified that letter at source. Set against a page that renders template code where prices should be, a 'no membership or hidden fees' claim sitting directly above a $99 membership tier, a reported no-refund-once-ordered position and a BBB F rating, the pattern is one of a company whose marketing outruns its disclosure. In fairness, MEDVi was one of 30 companies in an industry-wide FDA sweep, and the letter concerned claims rather than medication safety. If you use MEDVi anyway, do three things first: get a written price, get the refund terms in writing, and ask in writing which pharmacy compounds your medication.
Alternatives to MEDVi
Flat all-inclusive compounded pricing from a provider that names its 503A pharmacy partners outright.
Published compounded pricing from $86/month with no prepayment required.
Brand-name FDA-approved medication only, with a genuine insurance route.
Clear refund terms — a full refund if you are declined or cancel before shipment.
Compare more options on our best online GLP-1 providers and cheapest GLP-1 programs pages.
Frequently Asked Questions
Did MEDVi really receive an FDA warning letter?
Yes. We verified it in the FDA's own warning letter database. On 20 February 2026 the FDA's Center for Drug Evaluation and Research issued warning letter MARCS-CMS 721455 to MEDVi, LLC dba MEDVi, finding its compounded semaglutide and tirzepatide products misbranded under sections 502(a) and 502(bb) of the FDCA because the website's claims were false or misleading. MEDVi was one of 30 telehealth companies warned in a sweep the FDA announced on 3 March 2026, so it was not singled out — but the letter is real and specific.
What exactly did the FDA object to?
Two things. First, the compounded products pictured on MEDVi's website carried labels identifying 'MEDVi' as the compounder when, in the FDA's words, 'in fact it is not'. Second, claims that the products had the 'Same active ingredient as Wegovy® and Ozempic®' and 'Same active ingredient as Mounjaro® and Zepbound®' were found to imply FDA approval or evaluation that compounded products do not have. The letter concerned marketing claims, not a finding about the safety of the medication itself.
What does MEDVi cost?
We could not establish it. On 7 August 2026 the offer page we checked displayed unfilled template variables — 'Starting at ${seminject_sale_price}' — where the compounded injection and tablet prices should have been. Brand-name options were listed as '$99 Membership + Medication Cost' without stating the medication cost, on a page that also claims 'No membership or hidden fees'. Ask for a full written quote before paying anything.
Can I get a refund from MEDVi?
Probably not once your order is in motion. Reporting on MEDVi's terms indicates refunds are unavailable after an order has been placed and passed to a provider and then automatically to the pharmacy. We could not find a clearly published refund policy on the company's own site to verify that against. Get the refund terms in writing before you pay.
Is MEDVi the same company as MEDvidi?
No, and this trips up a lot of search results. MEDvidi (medvidi.com) is a separate mental health platform based in San Jose, California. Reviews and ratings for the two are frequently conflated online. This review concerns MEDVi, the GLP-1 telehealth service registered in Newark, Delaware.
Important Notes & Warnings
- This review is informational only and is not medical advice. Consult a licensed clinician before starting or changing treatment.
- REGULATORY: MEDVi received an FDA warning letter dated 20 February 2026 (MARCS-CMS 721455) finding its compounded semaglutide and tirzepatide products misbranded because of false or misleading website claims. The FDA warned that failure to address the violations 'may result in legal action without further notice, including, without limitation, seizure and injunction'.
- The FDA found MEDVi's product labels identified MEDVi as the compounder when it is not. Ask which pharmacy actually compounds your medication and confirm its 503A or 503B status.
- Compounded semaglutide and tirzepatide are NOT FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Mounjaro or Zepbound beyond the shared active ingredient.
- Pricing was not reliably displayed at the time of checking — obtain a full written quote before paying.
- Refunds are reportedly unavailable once an order has passed to the pharmacy.
- GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and in pregnancy.
- Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain; serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration.
Sources
- FDA Warning Letter, MEDVi, LLC dba MEDVi, MARCS-CMS 721455, 20 February 2026, Center for Drug Evaluation and Research (verified in FDA's warning letter database, accessed 7 August 2026)
- FDA press announcement, 'FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s', 3 March 2026
- MEDVi GLP-1 offer pages, glp1.medvi.org (accessed 7 August 2026)
- Better Business Bureau and third-party aggregate review summaries (indicative only; not independently verified)
Medical Disclaimer
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who has evaluated you can decide whether any medication is appropriate. Talk to a healthcare provider before starting, changing, or stopping any treatment, and call emergency services for urgent symptoms.
Facts in this review were compiled from the provider's own public website and public search results as of August 7, 2026. Prices, medication availability, pharmacy partners, and policies change frequently and vary by state — verify everything directly with the provider before purchasing.
This page contains affiliate links. We may earn a commission from qualifying purchases at no additional cost to you.